28, 33233329. Evaluation of the incidence of carboplatin hypersensitivity in cancer patients. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. Close monitoring is warranted for patients with any one of these three risk factors who are receiving carboplatin. Table 4. This Webinar series brings together all the relevant stakeholders who are developing each guideline, as well as those who are consulting and implementing the guideline. ESMO Clinical Practice Guidelines: Supportive and Palliative Care, ESMO Clinical Practice Guidelines on Palliative Care: Advanced Care Planning, Clinical Practice Guideline Anxiety and Depression, Anaemia and Iron Deficiency in Patients With Cancer, Clinical Practice Guidelines Management of Anaemia and Iron deficiency, Clinical Practice Guidelines Bone Health in Cancer Patients, Clinical Practice Guidelines Cancer Cachexia in Adult Patients, Clinical Practice Guidelines Management of cancer pain, Clinical Practice Guidelines - Cancer-related Fatigue, Clinical Practice Guidelines Care at the End of Life, Central Venous Access in Oncology: ESMO Clinical Practice Guidelines, Management of Chemotherapy Extravasation: ESMO Clinical Practice Guidelines, Clinical Practice Guidelines Constipation in advanced cancer, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. 18, 615620. doi: 10.1006/gyno.1994.1098, Keywords: ovarian cancer, chemotherapy, carboplatin, hypersensitivity, risk factor, Citation: Tai Y-H, Tai Y-J, Hsu H-C, Lee S-P, Chen Y-Y, Chiang Y-C, Chen Y-L, Chen C-A and Cheng W-F (2017) Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. In 74 of the 75 patients, the hypersensitivity reactions subsided within several minutes to several hours after onset, and the patients recovered without any sequelae. ESMO is a Swiss-registered not-for-profit organisation. Table 1. Optimal debulking surgery was performed in 491 patients (66.8%). 2014;24(2):72-9; quiz 2 p following 79. However, 48 (78.7%) of these patients developed repeated hypersensitivity reactions, even after pre-treatment with intravenous antihistamines, H2 blocker, and corticosteroids prior to carboplatin re-administration. Allergic and non-allergic ovarian cancer patients treated with carboplatin or carboplatin desensitization presented a similar life expectancy with a non significant advantage for the allergy desensitized patients. Necessary cookies enable core functionality. 144, 7782. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. *Correspondence: Wen-Fang Cheng, wenfangcheng@yahoo.com, Creative Commons Attribution License (CC BY). Federal government websites often end in .gov or .mil. J. Gynecol. Integrating science into oncology for a better patient outcome, ESMO Designated Centres Community Session, Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the. (2011) found that the number of treatment cycles with platinum-containing antineoplastic agents significantly correlates with the incidence of related hypersensitivity reactions. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Cancer 63, 2126. Webcasts and presentations from ESMO 2017 can be accessed by ESMO members and event attendees. We retrieved clinical information, including age, menopausal status, cancer stage, surgical findings, chemotherapeutic treatment history, recurrence status, and survivorship, from the clinical and operative notes and discharge summaries stored in a centralized database. Cumulative incidence of carboplatin-related hypersensitivity reactions according to the carboplatin administration cycle number (A) and carboplatin dose (B). Esmo | Esmo Hypersensitivity to antineoplastic agents. Gynecol. Educate. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan Carriers of BRCA genes develop drug allergy after fewer exposures and can present with severe reactions, including anaphylaxis. 2008;14(27):2892-901. doi: 10.2174/138161208786369803. However, basophil activation has been observed in patients with a history of severe carboplatin hypersensitivity reaction (Iwamoto et al., 2014). Overall, the evidence supports that the number of carboplatin cycles and dose are the principal risk factors for carboplatin-related hypersensitivity reactions, and that caution is warranted in cases of carboplatin infusion beyond 8 cycles or 3,500 mg. Carboplatin-related hypersensitivity reactions sometimes result in premature discontinuation of treatment (Schwartz et al., 2007). eCollection 2022 Apr. 3, 10 In subsequent trials, 11 - 16 patients were premedicated A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., et al. Table 7. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Before J. doi: 10.1093/annonc/mdy158. Severe carboplatin-related hypersensitivity reactions are uncommon. (33)]. Leuk Lymphoma. A cumulative carboplatin dose >4,000 mg significantly positively correlated with carboplatin hypersensitivity. European Hematology Association (EHA) and European . Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. Nitipir C, Parosanu A, Popa AM, Cotan H, Olaru M, Iaciu C, Orlov Slavu C. Cureus. Our findings also suggest that a history of drug or food allergies is a predictive factor for carboplatin-related hypersensitivity. 44, 837840. The total incidence of carboplatin-related hypersensitivity was 3.21% by the cycle of carboplatin. Ann Oncol. Clinical Practice Guidelines on Supportive Care - ESMO Have a look to the ESMO 2017 Programme online! 8600 Rockville Pike doi: 10.1200/JOP.18.00761. Invest. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Ke. Prevention and Management of Dermatological Toxicities Related to Anticancer Agents: ESMO Clinical Practice Guidelines. Zweizig, S., Roman, L. D., and Muderspach, L. I. 24, 2432. For more detailed information on the cookies we use, please check our Privacy Policy. Epub 2017 Feb 24. Timetrend analyses showed that most events were reported during the first 68 cycles with concurrent chemotherapy, with a decrease in later cycles (except MetaPHER). doi: 10.1111/j.1525-1438.2005.00136.x, Koshiba, H., Hosokawa, K., Kubo, A., Miyagi, Y., Oda, T., Miyagi, Y., et al. For more detailed information on the cookies we use, please check our Privacy Policy. Clipboard, Search History, and several other advanced features are temporarily unavailable. Drafting of manuscript: Y-HT and W-FC. Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010).